CompletedNCT02943304
Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universidad Industrial de Santander
- Principal Investigator
- Mario A Rojas, MD, MPHProfessor of Pediatrics
- Intervention
- Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV(other)
- Enrollment
- 284 target
- Eligibility
- 13-50 years · FEMALE
- Timeline
- 2016 – 2022
Study locations (1)
- Hospital Universitario de Santander, Bucaramanga, Santander Department, Colombia
Collaborators
University of North Carolina, Chapel Hill
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02943304 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)